Molecular imaging in neuroendocrine tumors

Recent advances, controversies, unresolved issues, and roles in management

Tetsuhide Ito, Robert T. Jensen

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Purpose of review: The purpose is to review recent advances in molecular imaging of neuroendocrine tumors (NETs), discuss unresolved issues, and review how these advances are affecting clinical management. Recent findings: Molecular imaging of NETs underwent a number of important changes in the last few years, leading to some controversies, unresolved issues, and significant changes in clinical management. The most recent changes are reviewed in this article. Particularly important is the rapid replacement in somatostatin receptor scintigraphy of 111In-diethylenetriamine penta-acetic acid-single-photon emission computed tomography/computed tomography (CT) by 68Ga-fluorodopa(F-D)PA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-peptide-PET/CT imaging, which is now approved in many countries including the USA. Numerous studies in many different types of NETs demonstrate the greater sensitivity of 68Ga-DOTA-peptide PET/CT, its high specificity, and its impact on management. Other important developments in somatostatin receptor scintigraphy/molecular imaging include demonstrating the prognostic value of both 68Ga-DOTA-peptide PET/CT and 18F-fluoro-deoxyglucose PET/CT; how their use can be complementary; comparing the sensitivities and usefulness of 68Ga-DOTA-peptide PET/CT and 18F-FDOPA PET/CT; introducing new linkers and radiolabeled ligands such as 64Cu-DOTA-peptides with a long half-life, enhancing utility; and the introduction of somatostatin receptor antagonists which show enhanced uptake by NETs. In addition, novel ligands which interact with other receptors (GLP-1, bombesin, cholecystokinin, gastric inhibitory polpeptide, integrin, chemokines) are described, which show promise in the imaging of both NETs and other tumors. Summary: Molecular imaging is now required for all aspects of the management of patients with NETs. Its results are essential not only for the proper diagnostic management of the patient, but also for assessing whether the patient is a candidate for peptide receptor radionuclide therapy with 177Lu and also for providing prognostic value.

Original languageEnglish
Pages (from-to)15-24
Number of pages10
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Volume24
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Molecular Imaging
Neuroendocrine Tumors
Tomography
Somatostatin Receptors
Peptides
Radionuclide Imaging
Ligands
Bombesin
Rubiaceae
Peptide Receptors
Cholecystokinin
Deoxyglucose
Chemokines
Integrins
Radioisotopes
Acetic Acid
Half-Life
Stomach
Neoplasms

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Nutrition and Dietetics

Cite this

Molecular imaging in neuroendocrine tumors : Recent advances, controversies, unresolved issues, and roles in management. / Ito, Tetsuhide; Jensen, Robert T.

In: Current Opinion in Endocrinology, Diabetes and Obesity, Vol. 24, No. 1, 01.01.2017, p. 15-24.

Research output: Contribution to journalReview article

@article{6ab8038f9280434c9a8f242f0cbd9674,
title = "Molecular imaging in neuroendocrine tumors: Recent advances, controversies, unresolved issues, and roles in management",
abstract = "Purpose of review: The purpose is to review recent advances in molecular imaging of neuroendocrine tumors (NETs), discuss unresolved issues, and review how these advances are affecting clinical management. Recent findings: Molecular imaging of NETs underwent a number of important changes in the last few years, leading to some controversies, unresolved issues, and significant changes in clinical management. The most recent changes are reviewed in this article. Particularly important is the rapid replacement in somatostatin receptor scintigraphy of 111In-diethylenetriamine penta-acetic acid-single-photon emission computed tomography/computed tomography (CT) by 68Ga-fluorodopa(F-D)PA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-peptide-PET/CT imaging, which is now approved in many countries including the USA. Numerous studies in many different types of NETs demonstrate the greater sensitivity of 68Ga-DOTA-peptide PET/CT, its high specificity, and its impact on management. Other important developments in somatostatin receptor scintigraphy/molecular imaging include demonstrating the prognostic value of both 68Ga-DOTA-peptide PET/CT and 18F-fluoro-deoxyglucose PET/CT; how their use can be complementary; comparing the sensitivities and usefulness of 68Ga-DOTA-peptide PET/CT and 18F-FDOPA PET/CT; introducing new linkers and radiolabeled ligands such as 64Cu-DOTA-peptides with a long half-life, enhancing utility; and the introduction of somatostatin receptor antagonists which show enhanced uptake by NETs. In addition, novel ligands which interact with other receptors (GLP-1, bombesin, cholecystokinin, gastric inhibitory polpeptide, integrin, chemokines) are described, which show promise in the imaging of both NETs and other tumors. Summary: Molecular imaging is now required for all aspects of the management of patients with NETs. Its results are essential not only for the proper diagnostic management of the patient, but also for assessing whether the patient is a candidate for peptide receptor radionuclide therapy with 177Lu and also for providing prognostic value.",
author = "Tetsuhide Ito and Jensen, {Robert T.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/MED.0000000000000300",
language = "English",
volume = "24",
pages = "15--24",
journal = "Current Opinion in Endocrinology, Diabetes and Obesity",
issn = "1752-296X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Molecular imaging in neuroendocrine tumors

T2 - Recent advances, controversies, unresolved issues, and roles in management

AU - Ito, Tetsuhide

AU - Jensen, Robert T.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose of review: The purpose is to review recent advances in molecular imaging of neuroendocrine tumors (NETs), discuss unresolved issues, and review how these advances are affecting clinical management. Recent findings: Molecular imaging of NETs underwent a number of important changes in the last few years, leading to some controversies, unresolved issues, and significant changes in clinical management. The most recent changes are reviewed in this article. Particularly important is the rapid replacement in somatostatin receptor scintigraphy of 111In-diethylenetriamine penta-acetic acid-single-photon emission computed tomography/computed tomography (CT) by 68Ga-fluorodopa(F-D)PA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-peptide-PET/CT imaging, which is now approved in many countries including the USA. Numerous studies in many different types of NETs demonstrate the greater sensitivity of 68Ga-DOTA-peptide PET/CT, its high specificity, and its impact on management. Other important developments in somatostatin receptor scintigraphy/molecular imaging include demonstrating the prognostic value of both 68Ga-DOTA-peptide PET/CT and 18F-fluoro-deoxyglucose PET/CT; how their use can be complementary; comparing the sensitivities and usefulness of 68Ga-DOTA-peptide PET/CT and 18F-FDOPA PET/CT; introducing new linkers and radiolabeled ligands such as 64Cu-DOTA-peptides with a long half-life, enhancing utility; and the introduction of somatostatin receptor antagonists which show enhanced uptake by NETs. In addition, novel ligands which interact with other receptors (GLP-1, bombesin, cholecystokinin, gastric inhibitory polpeptide, integrin, chemokines) are described, which show promise in the imaging of both NETs and other tumors. Summary: Molecular imaging is now required for all aspects of the management of patients with NETs. Its results are essential not only for the proper diagnostic management of the patient, but also for assessing whether the patient is a candidate for peptide receptor radionuclide therapy with 177Lu and also for providing prognostic value.

AB - Purpose of review: The purpose is to review recent advances in molecular imaging of neuroendocrine tumors (NETs), discuss unresolved issues, and review how these advances are affecting clinical management. Recent findings: Molecular imaging of NETs underwent a number of important changes in the last few years, leading to some controversies, unresolved issues, and significant changes in clinical management. The most recent changes are reviewed in this article. Particularly important is the rapid replacement in somatostatin receptor scintigraphy of 111In-diethylenetriamine penta-acetic acid-single-photon emission computed tomography/computed tomography (CT) by 68Ga-fluorodopa(F-D)PA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-peptide-PET/CT imaging, which is now approved in many countries including the USA. Numerous studies in many different types of NETs demonstrate the greater sensitivity of 68Ga-DOTA-peptide PET/CT, its high specificity, and its impact on management. Other important developments in somatostatin receptor scintigraphy/molecular imaging include demonstrating the prognostic value of both 68Ga-DOTA-peptide PET/CT and 18F-fluoro-deoxyglucose PET/CT; how their use can be complementary; comparing the sensitivities and usefulness of 68Ga-DOTA-peptide PET/CT and 18F-FDOPA PET/CT; introducing new linkers and radiolabeled ligands such as 64Cu-DOTA-peptides with a long half-life, enhancing utility; and the introduction of somatostatin receptor antagonists which show enhanced uptake by NETs. In addition, novel ligands which interact with other receptors (GLP-1, bombesin, cholecystokinin, gastric inhibitory polpeptide, integrin, chemokines) are described, which show promise in the imaging of both NETs and other tumors. Summary: Molecular imaging is now required for all aspects of the management of patients with NETs. Its results are essential not only for the proper diagnostic management of the patient, but also for assessing whether the patient is a candidate for peptide receptor radionuclide therapy with 177Lu and also for providing prognostic value.

UR - http://www.scopus.com/inward/record.url?scp=84997004528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997004528&partnerID=8YFLogxK

U2 - 10.1097/MED.0000000000000300

DO - 10.1097/MED.0000000000000300

M3 - Review article

VL - 24

SP - 15

EP - 24

JO - Current Opinion in Endocrinology, Diabetes and Obesity

JF - Current Opinion in Endocrinology, Diabetes and Obesity

SN - 1752-296X

IS - 1

ER -